Author

Nikola Vlahov

Cancer Research UK Scotland InstituteORCID 0009-0002-8649-6109Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Andrew D. CampbelliD· 2 shared Colin NixoniD· 2 shared Kathryn L. GilroyiD· 2 shared Owen James SansomiD· 2 shared Alison F. MunroiD· 1 shared Barbara Cadden· 1 shared Bryan SerrelsiD· 1 shared Catriona A. FordiD· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrew D. CampbellORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedDec 5, 2024

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

Catriona A. Ford, Dana Koludrović, Patricia P. Centeno…·Andrew D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

8 citations

mousehuman

𝕏 PostBluesky

Cancer BiologybioRxivPreprintNov 10, 2023

eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers

Joseph A. Waldron, Georgios Kanellos, Rachael C.L. Smith…·Owen James Sansom

This study shows eIF4A1 is critical for supporting translational demands in Wnt-driven colorectal cancers, while eIF4A2 loss accelerates tumourigenesis, and eFT226 inhibits eIF4A1 function in these models.

2 citations

mouseexperimental assay

𝕏 PostBluesky